University of Texas/Texas AM Investment Management Co (UTIMCO)’s Taysha Gene Therapies TSHA Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,147,040	Closed	-$13.4M	–	39
2021 Q4	$13.4M	Hold	1,147,040	–	–	6.07%	4
2021 Q3	$21.4M	Sell	1,147,040 -244,150	-18%	-$4.64M	12.2%	3
2021 Q2	$29.5M	Sell	1,391,190 -787,810	-36%	-$18.2M	22.62%	1
2021 Q1	$44.2M	Buy	2,179,000 +179,000	+9%	+$4.85M	25.95%	2
2020 Q4	$53.1M	Hold	2,000,000	–	–	57.48%	1
2020 Q3	$44.8M	Buy	+2,000,000	New	+$47M	46.63%	1

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s TSHA Position: Q1 2022 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of Taysha Gene Therapies (TSHA) in Q1 2022, closing a stake of 1,147,040 shares — an estimated $13.4M sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in TSHA in Q3 2020 and held it in 6 quarters. The position peaked at $53.1M in Q4 2020. 71 funds tracked by Wall St. Rank hold TSHA as of Q1 2022.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining Taysha Gene Therapies position as of Q1 2022 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 1,147,040 Taysha Gene Therapies shares in Q1 2022, an estimated $13.4M.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 6 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Taysha Gene Therapies position peaked at $53.1M in Q4 2020.
71 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2022.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q1 2022, filed 6 May 2022.